Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SDGR logo SDGR
Upturn stock ratingUpturn stock rating
SDGR logo

Schrodinger Inc (SDGR)

Upturn stock ratingUpturn stock rating
$19.45
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: SDGR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $29.7

1 Year Target Price $29.7

Analysts Price Target For last 52 week
$29.7 Target price
52w Low $16.6
Current$19.45
52w High $28.47

Analysis of Past Performance

Type Stock
Historic Profit -45.65%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.43B USD
Price to earnings Ratio -
1Y Target Price 29.7
Price to earnings Ratio -
1Y Target Price 29.7
Volume (30-day avg) 8
Beta 1.68
52 Weeks Range 16.60 - 28.47
Updated Date 08/15/2025
52 Weeks Range 16.60 - 28.47
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.48

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-06
When -
Estimate -0.8
Actual -0.65

Profitability

Profit Margin -76.22%
Operating Margin (TTM) -96.61%

Management Effectiveness

Return on Assets (TTM) -17.52%
Return on Equity (TTM) -44.4%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1095764174
Price to Sales(TTM) 6.02
Enterprise Value 1095764174
Price to Sales(TTM) 6.02
Enterprise Value to Revenue 4.61
Enterprise Value to EBITDA -10.82
Shares Outstanding 64441800
Shares Floating 58036838
Shares Outstanding 64441800
Shares Floating 58036838
Percent Insiders 2.62
Percent Institutions 101.73

ai summary icon Upturn AI SWOT

Schrodinger Inc

stock logo

Company Overview

overview logo History and Background

Schrodinger, Inc. was founded in 1990. It pioneered the use of physics-based computational methods to transform the way therapeutics and materials are discovered.

business area logo Core Business Areas

  • Drug Discovery: Develops its own pipeline of therapeutics programs by applying its computational platform, in addition to collaborating with pharmaceutical companies.
  • Software: Provides software solutions for computational chemistry and materials science to pharmaceutical, biotechnology, and chemical companies, as well as academic institutions and government laboratories.

leadership logo Leadership and Structure

Ramy Farid serves as Chief Executive Officer. The company has a board of directors and operates with a functional organizational structure.

Top Products and Market Share

overview logo Key Offerings

  • Schrodinger Drug Discovery Platform: A software platform used for drug discovery and materials science. Includes Maestro, PyMOL, and LiveDesign. Revenue from software and drug discovery services contribute significantly to overall revenue. Competitors include Dassault Systemes (BIOVIA), OpenEye Scientific, and ChemAxon.
  • Internal Drug Discovery Programs: Schrodinger is developing its own portfolio of drug candidates in areas like oncology, inflammation, and fibrosis. No reliable market share data available as these are drug candidates in development. Key players are major pharmaceutical and biotech companies such as Roche, Novartis, Pfizer, and Moderna.

Market Dynamics

industry overview logo Industry Overview

The computational drug discovery and materials science market is growing rapidly, driven by the increasing complexity of drug development, the need for faster and more efficient discovery processes, and advancements in computing power and AI.

Positioning

Schrodinger is a leader in physics-based computational methods for drug discovery, differentiating itself with a strong scientific foundation and integrated software platform.

Total Addressable Market (TAM)

The total addressable market for computational drug discovery is estimated to be in the tens of billions of dollars. Schrodinger is well-positioned to capture a significant share of this market due to its leading technology and established customer base.

Upturn SWOT Analysis

Strengths

  • Leading technology in physics-based computational methods
  • Integrated software platform
  • Strong scientific expertise
  • Established customer base
  • Proprietary drug discovery programs

Weaknesses

  • High R&D expenses
  • Dependence on key personnel
  • Long drug development timelines
  • Competition from larger, more diversified companies

Opportunities

  • Expanding into new therapeutic areas
  • Partnering with pharmaceutical companies
  • Leveraging AI and machine learning
  • Growing demand for computational drug discovery solutions
  • Expanding into new markets

Threats

  • Increasing competition
  • Changes in regulatory environment
  • Technological obsolescence
  • Failure of drug candidates in clinical trials
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • Dassault Systemes (DSY.PA)
  • OpenEye Scientific
  • Certara (CERT)
  • Chemical Computing Group

Competitive Landscape

Schrodinger has a competitive advantage in physics-based simulations, but faces competition from larger, more diversified companies.

Major Acquisitions

Pay-off Functional

  • Year: 2017
  • Acquisition Price (USD millions): 12
  • Strategic Rationale: Enhanced Schrodinger's free energy perturbation (FEP) capabilities.

Growth Trajectory and Initiatives

Historical Growth: Schrodinger has experienced strong revenue growth in recent years, driven by increased adoption of its software and services.

Future Projections: Analysts project continued revenue growth for Schrodinger, driven by its leading technology and expanding market opportunities.

Recent Initiatives: Schrodinger has recently invested in expanding its drug discovery pipeline and enhancing its AI capabilities.

Summary

Schrodinger is a leading computational drug discovery company with strong revenue growth, but is currently unprofitable due to heavy R&D spending. The company's technology is cutting edge, but it faces stiff competition. Drug discovery programs represent further potential upside. However, success rates are still uncertain.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Financial data is as of the latest available reporting period. Some stock tickers are foreign and data will not directly correlate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Schrodinger Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2020-02-06
CEO, President & Director Dr. Ramy Farid Ph.D.
Sector Healthcare
Industry Health Information Services
Full time employees 891
Full time employees 891

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.